Anti-human dlk-1 antibody showing anti-tumor activity in vivo
The present invention provides an antibody specifically against hDlk-1 and having anti-tumor activity in vivo (an anti-hDlk-1 antibody), a fragment of the antibody, a hybridoma that produces the antibody, a complex of the antibody or antibody fragment and an agent, a pharmaceutical composition comprising the antibody and the like, a tumor therapeutic agent, a tumor angiogenesis inhibitor, a tumor diagnostic agent, a method for detecting a tumor, a kit for detecting and/or diagnosing a tumor, etc.
1. An isolated antibody against human Dlk-1, which has anti-tumor activity in vivo, wherein the tumor is human liver cancer or human neuroblastoma, and wherein the amino acid sequences of CDRs 1 to 3 of the H chain V region of the antibody are the amino acid sequences as shown in SEQ ID NOS: 30 to 32, respectively and the amino acid sequences of CDRs 1 to 3 of the L chain V region of the antibody are the amino acid sequences as shown in SEQ ID NOS: 33 to 35, respectively.
2. The antibody according to claim 1 , wherein the anti-tumor activity is tumor angiogenesis-inhibiting activity.
3. The antibody according to claim 1 , which is a monoclonal antibody.
4. The antibody according to claim 1 , wherein the antibody is a genetically recombinant antibody.
5. The antibody according to claim 4 , wherein the genetically recombinant antibody is a chimeric antibody or a humanized antibody.
6. The antibody according to claim 5 , wherein the amino acid sequence of the H chain V region of the chimeric antibody comprises the amino acid sequence as shown in SEQ ID NO: 23 and the amino acid sequence of the L chain V region of the chimeric antibody comprises the amino acid sequence as shown in SEQ ID NO: 25.
7. The antibody according to claim 1 , which binds to a site, to which a monoclonal antibody produced by a hybridoma having accession no. FERM BP-10899 binds.
8. The antibody according to claim 1 , which binds to at least a portion of a region comprising amino acids at positions 92 to 167 in the amino acid sequence of human Dlk-1 as shown in SEQ ID NO: 2.
9. An isolated antibody fragment from the antibody according to claim 1 , wherein the antibody fragment comprises the amino acid sequences as shown in SEQ ID NOS: 30 to 32 and the amino acid sequences as shown in SEQ ID NOS: 33 to 35.
10. The antibody fragment according to claim 9 , which comprises the amino acid sequence as shown in SEQ ID NO: 23.
11. The antibody fragment according to claim 9 , which comprises the amino acid sequence as shown in SEQ ID NO: 25.
12. A monoclonal antibody produced by a hybridoma selected from the group consisting of a hybridoma having accession no. FERM BP-10707, a hybridoma having accession no. FERM BP-10899 and a hybridoma having accession no. FERM BP-10900.